United States - English - NLM (National Library of Medicine)

rising pharamceuticals, inc - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals inc. - griseofulvin (unii: 32hrv3e3d5) (griseofulvin - unii:32hrv3e3d5) - griseofulvin 500 mg - griseofulvin is indicated for the treatment of dermatophyte infections of the skin not adequately treated by topical therapy, hair and nails, namely: tinea corporis tinea pedis tinea cruris tinea barbae tinea capitis tinea unguium when caused by one or more of the following species of fungi: epidermophyton floccosum microsporum audouinii microsporum canis microsporum gypseum trichophyton crateriform trichophyton gallinae trichophyton interdigitalis trichophyton megnini trichophyton mentagrophytes trichophyton rubrum trichophyton schoenleini trichophyton sulphureum trichophyton tonsurans trichophyton verrucosum note: prior to therapy, a dermatophyte should be identified as responsible for the infection. prior to initiating treatment, appropriate specimens for laboratory testing (koh preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis. griseofulvin is not effective in the following: bacterial infections candidiasis (moniliasis) histoplasmosis actinomycosis sporotrichosis c

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc - griseofulvin (unii: 32hrv3e3d5) (griseofulvin - unii:32hrv3e3d5) - ultramicrosize griseofulvin tablets, usp are indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: trichophyton rubrum, trichophyton tonsurans, trichophyton mentagrophytes, trichophyton interdigitalis, trichophyton verrucosum, trichophyton megnini, trichophyton gallinae, trichophyton crateriform, trichophyton sulphureum, trichophyton schoenleini, microsporum audouini, microsporum canis, microsporum gypseum and epidermophyton floccosum . note: prior to therapy, the type of fungi responsible for the infection should be identified. the use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. griseofulvin is not effective in the following: bacterial i

United States - English - NLM (National Library of Medicine)

carilion materials management - disulfiram (unii: tr3mlj1uai) (disulfiram - unii:tr3mlj1uai) - disulfiram 250 mg - patients who are receiving or have recently received metronidazole, paraldehyde, alcohol, or alcohol-containing preparations, e.g., cough syrups, tonics and the like, should not be given disulfiram. disulfiram is contraindicated in the presence of severe myocardial disease or coronary occlusion, psychoses, and hypersensitivity to disulfiram or to other thiuram derivatives used in pesticides and rubber vulcanization.

United States - English - NLM (National Library of Medicine)

proficient rx lp - liothyronine sodium (unii: gca9vv7d2n) (liothyronine - unii:06lu7c9h1v) - thyroid hormone drugs are indicated: liothyronine sodium tablets can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. thyroid hormone preparations are generally contraindicated in patients with diagnosed but as yet uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis and apparent hypersensitivity to any of their active or extraneous constituents. there is no well-documented evidence from the literature, however, of true allergic or idiosyncratic reactions to thyroid hormone.

United States - English - NLM (National Library of Medicine)

proficient rx lp - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

United States - English - NLM (National Library of Medicine)

readymeds - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

United States - English - NLM (National Library of Medicine)

avkare - dofetilide (unii: r4z9x1n2nd) (dofetilide - unii:r4z9x1n2nd) - dofetilide capsules are indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [af/afl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. because dofetilide can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. in general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. recurrence is expected in some patients (see clinical studies ). dofetilide capsules are indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. dofetilide capsules have not been shown to be effective in patients with paroxysmal atrial fibrillation. dofetilide is contraindicated in patients with congenital or acquired long qt syndromes. dofetilide should not be used in patients with a baseline qt interval or qtc >440 msec (500 msec in patients with ventricular conduction abnormalities). dofetilide is also contraindicated in patients with severe renal impairment (calculated creatinine clearance <20 ml/min). the concomitant use of verapamil or the cation transport system inhibitors cimetidine, trimethoprim (alone or in combination with sulfamethoxazole), or ketoconazole with dofetilide is contraindicated (see warnings and precautions, drug-drug interactions ), as each of these drugs cause a substantial increase in dofetilide plasma concentrations. in addition, other known inhibitors of the renal cation transport system such as prochlorperazine, dolutegravir and megestrol should not be used in patients on dofetilide. the concomitant use of hydrochlorothiazide (alone or in combinations such as with triamterene) with dofetilide is contraindicated (see precautions, drug-drug interactions ) because this has been shown to significantly increase dofetilide plasma concentrations and qt interval prolongation. dofetilide is also contraindicated in patients with a known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

avkare - liothyronine sodium (unii: gca9vv7d2n) (liothyronine - unii:06lu7c9h1v) - liothyronine sodium tablets, usp are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. liothyronine sodium tablets, usp are indicated as an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer. liothyronine sodium tablets, usp are indicated as a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. limitations of use - liothyronine sodium tablets, usp are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with liothyronine sodium tablets, usp may induce hyperthyroidism [see warnings and precautions (5.4)]. - liothyronine sodium tablets, usp are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. liothyronine sodium tablets, usp are contraindicated in patients with uncorrected adrenal insufficiency [see  warnings and precautions (5.3)]. risk summary experience with liothyronine use in pregnant women, including data from post-marketing studies, have not reported increased rates of major birth defects or miscarriages (see data). there are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. since tsh levels may increase during pregnancy, tsh should be monitored and liothyronine sodium dosage adjusted during pregnancy (see clinical considerations). there are no animal studies conducted with liothyronine during pregnancy. liothyronine sodium tablets, usp should not be discontinued during pregnancy and hypothyroidism diagnosed during pregnancy should be promptly treated. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. disease-associated maternal and/or embryo/fetal risk maternal hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, gestational hypertension, pre-eclampsia, stillbirth, and premature delivery. untreated maternal hypothyroidism may have an adverse effect on fetal neurocognitive development. dose adjustments during pregnancy and the postpartum period pregnancy may increase liothyronine sodium requirements. serum tsh levels should be monitored and the liothyronine sodium dosage adjusted during pregnancy. since postpartum tsh levels are similar to preconception values, the liothyronine sodium dosage should return to the pre-pregnancy dose immediately after delivery [see dosage and administration (2.3)] . human data liothyronine is approved for use as a replacement therapy for hypothyroidism. data from post-marketing studies have not reported increased rates of fetal malformations, miscarriages, or other adverse maternal or fetal outcomes associated with liothyronine use in pregnant women. risk summary limited published studies report that liothyronine is present in human milk. however, there is insufficient information to determine the effects of liothyronine on the breastfed infant and no available information on the effects of liothyronine on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for liothyronine sodium and any potential adverse effects on the breastfed infant from liothyronine sodium or from the underlying maternal condition. the initial dose of liothyronine sodium tablets, usp varies with age and body weight. dosing adjustments are based on an assessment of the individual patient's clinical and laboratory parameters [see dosage and administration (2.3, 2.4)]. in pediatric patients in whom a diagnosis of permanent hypothyroidism has not been established, discontinue thyroid hormone for a trial period, but only after the child is at least 3 years of age. obtain serum tsh, t4, and t3 levels at the end of the trial period, and use laboratory test results and clinical assessments to guide diagnosis and treatment, if warranted [see dosage and administration (2.6)]. congenital hypothyroidism  [see dosage and administration (2.2, 2.6)] rapid restoration of normal serum t4 concentrations is essential for preventing the adverse effects of congenital hypothyroidism on intellectual development as well as on overall physical growth and maturation. therefore, initiate thyroid hormone immediately upon diagnosis. thyroid hormone is generally continued for life in these patients. closely monitor infants during the first 2 weeks of thyroid hormone therapy for cardiac overload, arrhythmias, and aspiration from avid suckling. closely monitor patients to avoid undertreatment or overtreatment. undertreatment may have deleterious effects on intellectual development and linear growth. overtreatment is associated with craniosynostosis in infants, may adversely affect the tempo of brain maturation, and may accelerate the bone age and result in premature epiphyseal closure and compromised adult stature [see dosage and administration (2.6) and adverse reactions (6)]. acquired hypothyroidism in pediatric patients closely monitor patients to avoid undertreatment and overtreatment. undertreatment may result in poor school performance due to impaired concentration and slowed mentation and in reduced adult height. overtreatment may accelerate the bone age and result in premature epiphyseal closure and compromised adult stature. treated children may manifest a period of catch-up growth, which may be adequate in some cases to normalize adult height. in children with severe or prolonged hypothyroidism, catch-up growth may not be adequate to normalize adult height [see adverse reactions (6)]. because of the increased prevalence of cardiovascular disease among the elderly, initiate liothyronine sodium tablets, usp at less than the full replacement dose [see dosage and administration (2.3) and  warnings and precautions (5.1)] . atrial arrhythmias can occur in elderly patients. atrial fibrillation is the most common of the arrhythmias observed with thyroid hormone overtreatment in the elderly.

United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - liothyronine sodium (unii: gca9vv7d2n) (liothyronine - unii:06lu7c9h1v) - liothyronine 25 ug - thyroid hormone drugs are indicated: 1. as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see warnings). 2. as pituitary thyroid-stimulating hormone (tsh) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (hashimoto’s) and multinodular goiter. 3.  as diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gl